Background COVID-19 seroprevalence data, particularly in less developed countries with a relatively low incidence, has been scant. We aimed to explore the seroprevalence of hospital staff in the area with zero confirmed COVID-19 case to shed light on the situation of COVID-19 infection in zero or low infection rate countries where mass screening was not readily available. Methods A locally developed rapid immunoglobulin M (IgM)/immunoglobulin G (IgG) test kit was used for hospital staff screening of Ranong hospital which is located in a province with zero COVID-19 prevalence in Thailand from 17 th April to 17 th May 2020. All staff was tested, 100 of which were randomly invited to have a repeating antibody test in one month. (Thai Clinical Trials Registry: TCTR20200426002) Results Of 844 hospital staff, 82 were tested twice one month apart (response rate for repeating antibody test 82%). Overall, 0.8% of the participants (7 of 844) had positive IgM, none had positive IgG. Female staff had 1.0% positive IgM (95% CI: 0.5–2.1%) while male had 0.5% positive IgM (95% CI: 0.1–2.6%). No participants with a history of travel to the high-risk area or close contact with PCR-confirmed COVID-19 case developed SARS-CoV-2 antibodies. Among 844 staff, 811 had no symptoms and six of them developed IgM seropositive (0.7%) while 33 had minor symptoms and only one of them developed IgM seropositive (3.0%). No association between SARS-CoV-2 IgM status and gender, history of travel to a high-risk area, close contact with PCR-confirmed or suspected COVID-19 case, presence of symptoms within 14 days, or previous PCR status was found. None of the hospital staff developed SARS-CoV-2 IgG. Conclusions COVID-19 antibody test could detect a considerable number of hospital staff who could be potential silent spreaders in a province with zero COVID-19 cases. Accurate antibody testing is a valuable screening tool, particularly in asymptomatic healthcare workers. Trial registration: This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and the Institutional Review Board of Ranong Hospital. (Thai Clinical Trials Registry: TCTR20200426002).
【초록키워드】 COVID-19, IgG, IgM, Antibody testing, hospital, Seroprevalence, Gender, Symptom, Hospital staff, Prevalence, Immunoglobulin G, SARS-CoV-2 antibodies, PCR, Mass screening, Asymptomatic, Immunoglobulin, COVID-19 infection, clinical, healthcare, male, Travel, Antibody test, infection rate, incidence, university, seropositive, SARS-CoV-2 IgG, SARS-CoV-2 IgM, association, close contact, COVID-19 cases, immunoglobulin M, response rate, contact with, no symptoms, institutional review board, Trial registration, 95% CI, PCR-confirmed, COVID-19 case, situation, COVID-19 antibody test, minor symptoms, participant, PCR-confirmed COVID-19, positive, confirmed COVID-19 case, country, IRB, Randomly, Result, tested, was used, detect, approved, less, had no, silent, Chulalongkorn, minor symptom, Ranong, was tested, 【제목키워드】 COVID-19 case,